Latest
No Correlation Between SF3B1 Mutation in Myelodysplastic Syndrome and Overall Survival
Antithrombin and Fibrinogen as Proxies for L-Asparaginase Activity in Pediatric Acute Lymphoblastic Leukemia
VTE-BLEED Risk Score Reliably Identifies Patients With PE at Risk for Major Bleeding
Outcomes With Eculizumab and Responses to Withdrawal for Atypical Hemolytic Uremic Syndrome
Presence of Autoimmune Diseases May Increase Risk for Diffuse Large B Cell, Marginal Zone Lymphomas
Whole Blood Ristocetin-Induced Platelet Aggregometry for Determining von Willebrand Disease Severity
Anemia in Atrial Fibrillation Linked to Increased Bleeding Risk
Prolonged-Release Anagrelide May Be Safe and Efficacious Against Thrombocythemia
Using Neural Networks to Assess Risk for Deep Vein Thrombosis
Discriminating Coagulation Patterns in Cyanotic, Noncyanotic Congenital Heart Disease
Relapse Risk in Pediatric Acute Myeloid Leukemia With Granulocyte Colony-Stimulating Factor
Standardization of Minimal Residual Disease Measurements in Philadelphia-Positive ALL
Featured Content
Measurable Residual Disease: A Step Toward Personalized Treatment for Acute Myeloid Leukemia
The presence of measurable residual disease may be a reliable predictor of relapse in patients with acute myeloid leukemia.
The Role of Cardiovascular Diseases in the Pathogenesis of Acquired von Willebrand Syndrome
High shear stress in blood vessels due to cardiovascular disease may be associated with the development of acquired von Willebrand syndrome.
Addressing Shortcomings in Management of Heavy Menstrual Bleeding in Adolescents
Because most studies on heavy menstrual bleeding have been conducted in adults, treatment guidelines for adolescents are lacking.
Data Mining to Develop Mutation-Specific Treatments in Acute Myeloid Leukemia
Integrating mutation-specific data across repositories and portals may lead to novel therapeutically actionable insights for acute myeloid leukemia.
Challenges Remain, New Therapies Needed for Pediatric Lymphoblastic Lymphoma
Treatment for lymphoblastic lymphomas may result in high morbidity and poor prognosis, highlighting the need for novel targeted therapeutic approaches.
